This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's Mad Dash: Starbucks and Celgene Have Upside

NEW YORK (TheStreet) -- Shares of Starbucks (SBUX - Get Report) caught an upgrade from UBS to buy from hold, while the analyst also bumped the price target to $87 from $80. 

On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, took at look at this "classic growth stock."

The stock has had trouble gaining upside momentum due to rising coffee costs, he reasoned.

However, CEO Howard Schultz has had to deal with rising input costs before, and has well positioned his company to deflect this rapid rise. 

Cramer added that investors are not paying too much for shares of Starbucks at current levels and he likes this analyst's call "very much." 

Turning to Celgene (CELG - Get Report), Credit Suisse boosted its price target on the stock to $225 from $210. 

The analyst reasoned that Celgene's pipeline is not being fully recognized, and Cramer seemed to agree. The advancements in creating possible cures for Crohn's disease and psoriatic arthritis are incredible and could be huge for Celgene, he concluded.

-- Written by Bret Kenwell in Petoskey, Mich.

IBM Fights for Respect and Relevance on Rough Seas of Investor Confidence

Why Big Car Companies Don't Give A Rat's Ass About Tesla

5 Reasons to Change Your Outlook on Emerging Markets

Why SolarCity Is Shining Once Again for Investors

At the time of publication, Cramer's Action Alerts PLUS holds CELG.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CELG $131.18 -0.22%
SBUX $58.69 1.10%
AAPL $114.64 -3.21%
FB $94.06 -0.08%
GOOG $630.13 -0.17%

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs